Scientific Advisory Board

Marianna Castells, M.D., Ph.D.


  • Professor, Harvard Medical School, Allergy and Immunology; 
  • Director, Adverse Drug Reaction and Desensitization Program at Brigham and Women's Hospital

Mark S. Freedman, M.D.


  • Professor, University of Ottawa
  • Executive Director, MS Research Unit at the Ottawa Hospital
  • Lead Investigator, Canadian Bone Marrow Transplant Study in MS
  • Director, Canadian Mesenchymal Stem Cell Transplantation in MS Study 
  • Co-Director, International Mesenchymal Stem Cell Transplantation in MS Study Group. 
  • Treasurer of the Americas Committee for Treatment and Research in MS (ACTRIMS).

Adam Kaplin, M.D., Ph.D.


  • Assistant Professor, Department of Psychiatry, Division of Neuropsychiatry
  • Chief Psychiatric Consultant, Multiple Sclerosis and Transverse Myelitis Clinics, Department of Neurology
  • Attending Physician, HIV/AIDS Psychiatry Service,  Department of Psychiatry
  • Johns Hopkins University School of Medicine

Timothy Riley, Ph.D.


Emotionally intelligent, entrepreneurial Executive in the pharmaceutical and biotechnology industry with multiple drugs approved and approaching approval. These products are projected to be multi-billion dollar products and have created over $6 billion in market capitalization. Built and led successful teams in pharmaceutical research and development with over three decades of experience. Leadership positions include Executive position in business development for a top tier research medical school, decade long tenure as Executive Committee member of a publicly traded company, SVP of Global Research, and SVP of Quality. Directed internal and external international relationships. Therapeutic areas include Rare Diseases, Hemophilia, Pain, Oncology, Antivirals.